Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe ulcerative colitis outpatient~* Disease duration at time of screening of \>/= 12 weeks~Exclusion Criteria:~* Extensive colonic resection or subtotal or total colectomy~* Presence of an ileostomy or colostomy~* Moderate to severe anemia~* A history or evidence of colonic mucosal dysplasia~* Pregnant or lactating~* Significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disorders~* Significant screening ECG abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block~* Poorly controlled diabetes~* Impaired renal function~* Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis~* Positive tests for antibodies indicating active or prior infection with HIV or hepatitis B (HBV) or C (HCV)~* Positive screening test for latent mycobacterium tuberculosis (TB) infection~* Demyelinating disease~* Received any investigational treatment within 12 weeks prior to initiation of study treatment~* Previous exposure to rhuMAb Beta7

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- rhuMAb Beta7 (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).